160 related articles for article (PubMed ID: 7458992)
1. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
Hunninghake DB; Bell C; Olson L
Atherosclerosis; 1980 Nov; 37(3):469-74. PubMed ID: 7458992
[TBL] [Abstract][Full Text] [Related]
2. [Clinical research on the hypolipidemic action of a probucol preparation].
Naumova R; Kerekovska M; Goranov I; Balabanski L
Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
[TBL] [Abstract][Full Text] [Related]
3. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G
Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013
[TBL] [Abstract][Full Text] [Related]
4. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J
J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383
[TBL] [Abstract][Full Text] [Related]
5. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia.
Mellies MJ; Gartside PS; Glatfelter L; Vink P; Guy G; Schonfeld G; Glueck CJ
Metabolism; 1980 Oct; 29(10):956-64. PubMed ID: 6999291
[No Abstract] [Full Text] [Related]
6. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
[TBL] [Abstract][Full Text] [Related]
7. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
Cortese C; Marenah CB; Miller NE; Lewis B
Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396
[TBL] [Abstract][Full Text] [Related]
8. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
[TBL] [Abstract][Full Text] [Related]
9. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
Artery; 1993; 20(1):1-18. PubMed ID: 8447724
[TBL] [Abstract][Full Text] [Related]
10. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
[TBL] [Abstract][Full Text] [Related]
11. The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
Dachet C; Jacotot B; Buxtorf JC
Atherosclerosis; 1985 Dec; 58(1-3):261-8. PubMed ID: 4091882
[TBL] [Abstract][Full Text] [Related]
12. Probucol in hypercholesterolemia. A double blind study.
Riesen WF; Keller M; Mordasini R
Atherosclerosis; 1980 Jun; 36(2):201-7. PubMed ID: 7406949
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Rezzonico L; Chiesa G; Sirtori CR
Arteriosclerosis; 1989; 9(4):462-9. PubMed ID: 2751476
[TBL] [Abstract][Full Text] [Related]
14. Modifications in the chemical composition and thermometric behavior of LDL and HDL by probucol in type IIa hyperlipoproteinemia.
Dachet C; Motta C; Neufcour D; Jacotot B
Adv Exp Med Biol; 1988; 243():179-84. PubMed ID: 3223415
[No Abstract] [Full Text] [Related]
15. Effects of probucol on the composition and in vitro catabolism of LDL in type IIa hypercholesterolemia.
Baudet MF; Esteva O; Dachet C; Jacotot B
Atherosclerosis; 1986 Oct; 62(1):65-71. PubMed ID: 3778575
[TBL] [Abstract][Full Text] [Related]
16. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
17. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
[TBL] [Abstract][Full Text] [Related]
18. Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol.
Sirtori CR; Sirtori M; Calabresi L; Franceschini G
Am J Cardiol; 1988 Jul; 62(3):73B-76B. PubMed ID: 3293417
[TBL] [Abstract][Full Text] [Related]
19. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
Hunninghake DB; Bell C; Olson L
Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
[TBL] [Abstract][Full Text] [Related]
20. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
